High-dose methotrexate, vincristine and cisplatin as salvage treatment for relapsed non-seminomatous germ-cell cancer
Sleijfer, S.; Van der Graaf, W.T.; Willemse, P.H.; De Vries, E.G.; Schraffordt Koops, H.; Mulder, N.H.
Anticancer Research 15(3): 1039-1042
1995
ISSN/ISBN: 0250-7005 PMID: 7544087 Document Number: 446813
Eight patients with non-seminomatous testicular cancer relapsing after primary chemotherapy were treated with salvage chemotherapy consisting of high-dose methotrexate (12 g/m-2 ), vincristine (1.2 mg/m-2 weekly for four weeks, followed after an interval of four weeks by 3 times 100 mg/m-2 cisplatin (50 mg/m-2 on day 1 and 2) every 10 days. This regimen resulted in 2 partial (PR) and 2 complete responses (CR). The two patients achieving CR remain disease-free for 43+ and 53 months. Toxicity was mainly methotrexate-related and could be ameliorated to a large extent by leucovorin rescue. This small study shows that methotrexate, vincristine, followed by cisplatin is effective in the treatment of relapsed non-seminomatous testicular cancer at the cost of manageable toxicity.